Jardiance ® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Jardiance | Research | Urology & Nephrology